You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 111 No. 12, December 1993 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinical Sciences
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (23)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Pentoxifylline Increases Retinal Capillary Blood Flow Velocity in Patients With Diabetes

Peter L. Sonkin, MD; Larry W. Kelly; Stephen H. Sinclair, MD; Diane L. Hatchell, PhD

Arch Ophthalmol. 1993;111(12):1647-1652.


Abstract

Objective
The purpose of this study was to determine whether oral pentoxifylline would improve retinal microvascular hemodynamics and blood rheology in patients with diabetes.

Design
Patients were enrolled in a double-masked, placebocontrolled trial of pentoxifylline at 2000 mg/d. Retinal capillary blood velocity and leukocyte density, filterability, viscosity, and fibrinogen content were measured by the bluefield entoptic phenomenon simulation, filtration, rotational viscosimetry, and heat precipitation techniques, respectively, before, during, and after drug therapy.

Results
Treatment with pentoxifylline resulted in a 23.2%, 26.8%, and 37.8% increase in capillary blood flow velocity at 1, 2, and 3 months of therapy, respectively, with a return to pretreatment baseline levels 1 month after cessation of therapy. There were no apparent effects on the remaining variables during treatment.

Conclusion
Pentoxifylline increases retinal capillary blood flow velocity in patients with diabetes.



Author Affiliations

From the Departments of Ophthalmology and Cell Biology, Duke University Medical Center, and Durham Veterans Affairs Medical Center, Durham, NC (Drs Sonkin and Hatchell and Mr Kelly), and Department of Ophthalmology, Hahnemann University School of Medicine, Philadelphia, Pa (Dr Sinclair). Dr Sonkin is currently a resident in the Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas. The authors have no personal or financial interests in the materials or methods used in this study.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Wall-to-Lumen Ratio of Retinal Arterioles and Arteriole-to-Venule Ratio of Retinal Vessels in Patients with Cerebrovascular Damage
Baleanu et al.
IOVS 2009;50:4351-4359.
ABSTRACT | FULL TEXT  

Effects of Pentoxifylline and Alprostadil on Ocular Hemodynamics in Healthy Humans
Dorner et al.
IOVS 2007;48:815-819.
ABSTRACT | FULL TEXT  

Pentoxifylline Inhibition of Vasculogenesis in the Neonatal Rat Retina
Hasebe et al.
IOVS 2000;41:2774-2778.
ABSTRACT | FULL TEXT  

Short-term Oral Pentoxifylline Use Increases Choroidal Blood Flow in Patients With Age-related Macular Degeneration
Kruger et al.
Arch Ophthalmol 1998;116:27-30.
ABSTRACT | FULL TEXT  

Effects of Pentoxifylline on Choroidal Blood Flow in Nonproliferative Diabetic Retinopathy
Sebag et al.
ANGIOLOGY 1994;45:429-433.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.